Human Papillomavirus – Role in Cervical Carcinogenesis and Methods of Detection

Česká verzia

Authors: Bartošík Martin; Hrstka Roman; Jiráková Ludmila
Authors place of work: RECAMO, Masarykův onkologický ústav, Brno
Published in the journal: Klin Onkol 2018; 31(2): 89-94
Category: Review
doi: https://doi.org/10.14735/amko201889

Summary

Background:
Persistent infection with high-risk human papillomavirus (HPV) strains, especially HPV 16 and HPV 18, is associated with the onset of various malignant diseases, including cervical carcinoma in women. HPV DNA testing is thus being implemented as a complementary method to standard cytological examination, mainly due to its increased sensitivity.

Aim:
This review outlines the role of HPV in cervical carcinogenesis, with a focus on the formation of cervical intraepithelial neoplasias (CIN1–3) and the molecular mechanism underlying cellular transformation. Current biomarkers used to screen premalignant lesions are described, including mRNA transcripts of the E6 and E7 genes, protein p16 (a cyclin-dependent kinase inhibitor that regulates cell cycle progression from G1 to S phase), altered DNA methylation patterns, and actions of specific microRNAs (short (18–22 bp), non-coding, single-stranded RNA molecules that regulate gene expression at the post-transcriptional level). This review also describes the advantages and drawbacks of commercial HPV tests, and depicts novel methods for more cost-effective and faster HPV diagnostics based on optical or electrochemical detection.

Conclusion:
Although great progress has been made, the incidence and mortality rates of cervical malignancies remain relatively high, especially in developing countries. Incorporation of HPV testing into routine screening programs could help to decrease mortality rates; however, the cost of such testing must be reduced if it is to compete with current cytology-based examinations.

Key words:
HPV – cervical carcinoma – HPV testing – nucleic acid hybridization – mRNA – DNA methylation – microRNA

This work was supported by MEYS-NPS I-LO1413 and GAČR 17-08971S.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
25. 9. 2017

Accepted:
26. 1. 2018

Zdroje

1. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003; 16 (1): 1–17.

2. Schiffman M, Castle PE, Jeronimo J et al. Human papillomavirus and cervical cancer. Lancet 2007; 370 (9590): 890–907. doi: 10.1016/S0140-6736 (07) 61416-0.

3. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006; 11: 2286–2302.

4. Graham SV. Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. Future Microbiol 2010; 5 (10): 1493–1506. doi: 10.2217/fmb.10.107.

5. Origoni M, Cristoforoni P, Carminati G et al. E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective. Ecancermedicalscience 2015; 9: 533. doi: 10.3332/ecancer.2015.533.

6. Munkhdelger J, Kim G, Wang HY et al. Performance of HPV E6/E7 mRNA RT-qPCR for screening and diagnosis of cervical cancer with ThinPrep® Pap test samples. Exp Mol Pathol 2014; 97 (2): 279–284. doi: 10.1016/j.yexmp.2014.08.004.

7. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008; 17 (10): 2536–2545. doi: 10.1158/1055-9965.EPI-08-0306.

8. Darragh TM, Colgan TJ, Cox JT et al. The Lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the college of american pathologists and the american society for colposcopy and cervical pathology. Arch Pathol Lab Med 2012; 136 (10): 1266–1297. doi: 10.5858/arpa.LGT200570.

9. Clarke MA, Wentzensen N, Mirabello L et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev 2012; 21 (12): 2125–2137. doi: 10.1158/1055-9965.EPI-12-0905.

10. Bhattacharjee B, Sengupta S. CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology 2006; 354 (2): 280–285. doi: 10.1016/j.virol.2006.06.018.

11. Vinokurova S, von Knebel Doeberitz M. Differential methylation of the HPV 16 upstream regulatory region during epithelial differentiation and neoplastic transformation. Plos One 2011; 6 (9): e24451. doi: 10.1371/journal.pone.0024451.

12. Hublarová P, Hrstka R, Rotterová P et al. Prediction of human papillomavirus 16 E6 gene expression and cervical intraepithelial neoplasia progression by methylation status. Int J Gynecol Cancer 2009; 19 (3): 321–325. doi: 10.1111/IGC.0b013e31819d8a5c.

13. Steenbergen RD, Snijders PJ, Heideman DA et al. Clinical implications of (epi) genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014; 14 (6): 395–405. doi: 10.1038/nrc3728.

14. Kalantari M, Chase DM, Tewari KS et al. Recombination of human papillomavirus-16 and host DNA in exfoliated cervical cells: A pilot study of L1 gene methylation and chromosomal integration as biomarkers of carcinogenic progression. J Med Virol 2010; 82 (2): 311–320. doi: 10.1002/jmv.21676.

15. Bartošík M, Ondroušková E. Nové metody studia metylace DNA – MS-HRM analýza a elektrochemie. Klin Onkol 2016; 29 (Suppl 4): 64–71. doi: 10.14735/amko20164S64.

16. Sharma G, Dua P, Agarwal SM. A comprehensive review of dysregulated miRNAs involved in cervical cancer. Curr Genomics 2014; 15 (4): 310–323. doi: 10.2174/1389202915666140528003249.

17. Ondryášová H, Koudeláková V, Hajdúch M. Karcinom cervixu – možnosti detekce lidského papilomaviru. Čes Gynek 2013; 78 (3): 289–294.

18. Ronco G, Segnan N, Giorgi-Rossi P et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98 (11): 765–774. doi: 10.1093/jnci/djj209.

19. Morris BJ. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. Clin Chem Lab Med 2005; 43 (11): 1171–1177. doi: 10.1515/CCLM.2005.203

20. The American cancer society medical and editorial content team. HPV and HPV Testing. [online]. Available from: https: //www.cancer.org/cancer/cancer-causes/infectious-agents/hpv/hpv-and-hpv-testing.html.

21. Xu Y, Liu Y, Wu Y et al. Fluorescent probe-based lateral flow assay for multiplex nucleic acid detection. Anal Chem 2014; 86 (12): 5611–5614. doi: 10.1021/ac5010458.

22. Kumvongpin R, Jearanaikoon P, Wilailuckana C et al. Detection assay for HPV16 and HPV18 by loop-mediated isothermal amplification with lateral flow dipstick tests. Mol Med Rep 2017; 15 (5): 3203–3209. doi: 10.3892/mmr.2017.6370.

23. Bartošík M, Paleček E, Vojtěšek B. Elektrochemická analýza nukleových kyselin, bílkovin a polysacharidů v biomedicíně. Klin Onkol 2014; 27 (Suppl 1): 53–60. doi: 10.14735/amko20141S53.

24. Paleček E, Bartošík M. Electrochemistry of nucleic acids. Chem Rev 2012; 112 (6): 3427–3481. doi: 10.1021/cr200303p.

25. Huang H, Bai W, Dong C et al. An ultrasensitive electrochemical DNA biosensor based on graphene/Au nanorod/polythionine for human papillomavirus DNA detection. Biosens Bioelectron 2015; 68: 442–446. doi: 10.1016/j.bios.2015.01.039.

26. Karimizefreh A, Mahyari FA, VaezJalali M et al. Impedimetic biosensor for the DNA of the human papilloma virus based on the use of gold nanosheets. Microchim Acta 2017; 184 (14): 1729–1737. doi: 10.1007/s00604-017-2173-8.

27. Bartošík M, Ďuríková H, Vojtěšek B et al. Electrochemical chip-based genomagnetic assay for detection of high-risk human papillomavirus DNA. Biosens Bioelectron 2016; 83: 300–305. doi: 10.1016/j.bios.2016.04.035.

28. Lin J, Ma B, Fang J et al. Colorimetric detection of 23 human papillomavirus genotypes by loop-mediated isothermal amplification. Clin Lab 2017; 63 (3): 495–505. doi: 10.7754/Clin.Lab.2016.160906.

29. Persano S, Valentini P, Kim JH et al. Colorimetric detection of human papilloma virus by double isothermal amplification. Chem Commun 2013; 49 (90): 10605–10607. doi: 10.1039/c3cc45459b.

30. Saetiew C, Limpaiboon T, Jearanaikoon P et al. Rapid detection of the most common high-risk human papillomaviruses by loop-mediated isothermal amplification. J Virol Methods 2011; 178 (1–2): 22–30. doi: 10.1016/j.jviromet.2011.08.007.